GSK Looks To Immuno-Neurology In $700m Alector Tie-up
Return to neuroscience follows activist investor showdown
Alector says upfront payment and earnouts will fully pay for development of AL101 and AL001 in frontotemporal dementia and indications including ALS, Alzheimer’s and Parkinson’s.
